Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

SECTION EDITOR'S NOTE: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have included capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib. These medications have dou...

Full description

Saved in:
Bibliographic Details
Main Authors: Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2012
Subjects:
Challenging Cases
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500363/
https://ncbi.nlm.nih.gov/pubmed/23073991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0075
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items